Shares of Genus plc (LON:GNS – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 2,504.08 and traded as high as GBX 2,610. Genus shares last traded at GBX 2,595, with a volume of 350,101 shares.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Shore Capital raised their price target on shares of Genus from GBX 2,900 to GBX 3,000 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Berenberg Bank assumed coverage on shares of Genus in a research note on Tuesday, November 25th. They issued a “buy” rating and a GBX 3,050 target price for the company. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on Genus from GBX 2,900 to GBX 3,100 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, Genus has an average rating of “Buy” and an average target price of GBX 3,050.
Check Out Our Latest Report on Genus
Genus Stock Performance
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Read More
- Five stocks we like better than Genus
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
